IP Verse

Amgen, Inc opposition analysis

COMPANY ANALYSIS

Latest patents of Amgen, Inc opposed by its competitors

Patent:
EP2301961
Grant Date:
Dec 13, 2023
Title:
Sclerostin Epitopes
Oppositions:
1
Patent:
EP2445924
Grant Date:
Dec 13, 2023
Title:
Capture Purification Processes For Proteins Expressed In A Non-Mammalian System
Oppositions:
1
Patent:
EP3666797
Grant Date:
May 17, 2023
Title:
Antigen Binding Proteins To Proprotein Convertase Subtilisin Kexin Type 9 (Pcsk9)
Oppositions:
2
Patent:
EP3434760
Grant Date:
Apr 26, 2023
Title:
Methods For Increasing Mannose Content Of Recombinant Proteins
Oppositions:
1
Patent:
EP3521440
Grant Date:
Feb 9, 2022
Title:
Methods For Harvesting Mammalian Cell Cultures
Oppositions:
1
Patent:
EP2345668
Grant Date:
Sep 22, 2021
Title:
Sclerostin Epitopes
Oppositions:
1
Patent:
EP3670528
Grant Date:
Sep 8, 2021
Title:
Sclerostin Binding Agents
Oppositions:
1
Patent:
EP3395339
Grant Date:
Dec 11, 2019
Title:
Rapid Dissolution Formulation Of A Cinacalcet Hcl
Oppositions:
11
Patent:
EP3395340
Grant Date:
Dec 11, 2019
Title:
Rapid Dissolution Formulation Of Cinacalcet Hcl
Oppositions:
9
Patent:
EP3260117
Grant Date:
Nov 27, 2019
Title:
Rapid Dissolution Formulation Of A Calcium Receptor-Active Compound
Oppositions:
10

Competitors of Amgen, Inc

AECHTER, BERND

BIOGARAN

GLENMARK PHARMACEUTICALS EUROPE LTD

Want to track Amgen, Inc?

Feel free to send us a message here and we will get back to you